Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics March 5, 2019 - NASDAQ Companies 0 » View More News for March 05, 2019
